The Ontario Institute for Cancer Research

Dr. Paul Boutros

OICR Fellow

Research Description

Today, most cancer patients are treated based on physical characteristics of their tumour -- usually how large it is and how far it has spread.  A major part of Dr. Boutros' research is to supplement these traditional clinical criteria with new molecular ones.  For example, can we personalize the treatment of lung and breast cancer patients based on mRNA profiles of their tumours?  Dr. Boutros is developing novel computational techniques focused on answering this type of question. 


Contact Information

Telephone
416-673-8564

Mailing Address
Ontario Institute for Cancer Research
MaRS Centre, South Tower
101 College Street, Suite 800
Toronto, Ontario
Canada M5G 0A3

Current

2008 - Fellow, Informatics and Biocomputing Platform, Ontario Institute for Cancer Research.


Background        

2008 PhD, Department of Medical Biophysics, University of Toronto.
2001 - 2004 Bioinformatics Researcher, Department of Pharmacology, University of Toronto.
2000 - 2001 Bioinformatics Researcher, Department of Biochemistry, Michigan State University.
2004 B.Sc., Chemistry, Honours Co-operative Education, University of Waterloo.

                                             

Selected Publications

  1. Boutros PC, Lau SK, Pintilie M, Shepherd FA, Der SD, Tsao MS, Penn LZ, Jurisica I. Prognostic Gene Signatures for Non-Small Cell Lung Cancer. Proceedings of the National Academy of Sciences 2009;106(8):2824-8.

  2. Boutros PC, Ponzielli R, Katz S, Stojanova A, Hanley AP, Khosravi F, Bros C, Jurisica I, Penn LZ. Optimization of experimental design parameters for high-throughput chromatin immunoprecipitation studies. Nucleic Acids Research. 2008;36(21):e144

  3. Boutros PC, Yan R, Moffat ID, Pohjanvirta R, Okey AB. Transcriptomic responses to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in liver: comparison of rat and mouse. BMC Genomics. 2008;16:9(419)

  4. Lau SK, Boutros PC, Pintilie M, Blackhall FH, Zhu CQ, Strumpf D, Johnston MR, Darling G, Keshavjee S, Waddell TK, Liu N, Lau D, Penn LZ, Shepherd FA, Jurisica I, Der SD, Tsao MS. Three-gene prognostic classifier for early-stage non small-cell lung cancer. Journal of Clinical Oncology. 2007;25(35):5562-5569

  5. Tijet N, Boutros PC, Moffat ID, Okey AB, Tuomisto J, Pohjanvirta R. Aryl hydrocarbon receptor regulates distinct dioxin-dependent and dioxin-independent gene batteries. Molecular Pharmacology. 2006;69(1):140-153

back   top